Neuralink's First 10 Patients Can Control Computers With Their Thoughts — and the Results Are Remarkable
Neuralink has published its first peer-reviewed clinical data in the New England Journal of Medicine, and the results exceed what even optimistic observers expected. All 10 participants in the company's PRIME (Precise Robotically Implanted Brain-Computer Interface) trial — each living with quadriplegia or ALS — have successfully used the N2 implant to control digital devices through thought alone, with accuracy rates averaging 97.3% and no serious adverse events over the 12-month study period.
What Patients Can Do
The capabilities demonstrated in the trial go well beyond the cursor movement that made headlines with Neuralink's first patient in 2024. Participants can now type at speeds averaging 62 words per minute (comparable to average smartphone typing speed), navigate smartphone interfaces including messaging and web browsing, control robotic arms to perform tasks like pouring water and opening containers, and play video games requiring real-time precision.
One participant, a 34-year-old man with C4 spinal cord injury, described the experience: "Within two weeks, it felt as natural as moving my hand used to feel. I don't think about controlling a cursor — I just look where I want to click and it happens. It's given me back a life I thought was gone."
The N2 Implant
The second-generation Neuralink device, called N2, represents significant improvements over the original. It contains 4,096 electrodes (up from 1,024 in N1), distributed across 128 ultra-thin threads implanted in the motor cortex and posterior parietal cortex. The device is fully wireless, charges inductively through the skull while the patient sleeps, and processes neural signals using an on-chip AI model that continuously adapts to each user's unique neural patterns.
The surgical implantation, performed by Neuralink's R1 robot, takes approximately 45 minutes and requires no general anesthesia — patients are sedated but conscious throughout the procedure. The robot's precision is critical: each electrode thread is thinner than a human hair and must be placed to avoid blood vessels visible only under microscopic imaging.
Safety Profile
The study's most significant finding may be the safety data. None of the 10 participants experienced infection, hemorrhage, or neurological deterioration. Two participants experienced minor headaches in the first week post-implantation, which resolved without treatment. The threads showed no measurable migration over the 12-month period, and the electrodes maintained consistent signal quality — addressing a concern that had plagued earlier BCI designs.
Independent neurologists reviewing the data noted that the safety profile is "remarkably clean for a first-in-human trial of this complexity," though they cautioned that 10 patients over 12 months is a small sample from which to draw definitive safety conclusions.
Competition and Context
Neuralink isn't the only company developing brain-computer interfaces. BrainGate, the academic consortium that pioneered the field, has published data on implants that have functioned for over 7 years in some patients. Synchron's Stentrode, which is implanted through blood vessels rather than open brain surgery, has completed trials in 16 patients with a less invasive approach. Precision Neuroscience's Layer 7 cortical interface offers a middle ground between invasiveness and electrode density.
But Neuralink's combination of electrode count, wireless operation, AI-powered signal processing, and robotic surgical precision represents the most integrated system yet — and its results reflect that integration advantage.
Regulatory Path and Future
The FDA has granted Neuralink Breakthrough Device designation, which accelerates the regulatory review process. The company plans to expand its trial to 50 patients in 2026 and is targeting commercial availability for paralysis patients by late 2027, pending regulatory approval.
Musk has been characteristically ambitious about the technology's long-term potential — suggesting that healthy individuals might eventually use Neuralink to enhance cognitive capabilities. But the company's clinical team has been careful to focus on the immediate medical applications: restoring communication and independence to people who have lost them.
For now, that's more than enough. The 10 patients in this trial have regained abilities that their conditions had taken from them. That's not science fiction — it's medicine.
